(4R)-4-(2-aminoethylcarbamoylamino)pentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-4-(2-aminoethylcarbamoylamino)pentanoic acid
• 化学式: C₈H₁₇N₃O₃
• 分子量: 203.24
• InChiKey: GLKZORGNCPUFTF-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  104
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same
  申请人：BIND Therapeutics, Inc.

  公开号：US20140178475A1

  公开（公告）日：2014-06-26

  The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.
• THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME
  申请人：Pfizer Inc.

  公开号：US20150258102A1

  公开（公告）日：2015-09-17

  The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.
• NANOPARTICLES COMPRISING DOCETAXEL FOR TREATING CANCERS HAVING A K-RAS MUTATION
  申请人：BIND THERAPEUTICS, INC.

  公开号：US20170042855A1

  公开（公告）日：2017-02-16

  The present disclosure relates in part to methods of treating cancers having a mutation in a Ras gene in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein the nanoparticle composition comprises nanoparticles.
• METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES
  申请人：PFIZER INC.

  公开号：US20170151181A1

  公开（公告）日：2017-06-01

  The present disclosure relates in part to methods of treating cancers having a mutation in a Ras gene in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein the nanoparticle composition comprises nanoparticles.
• Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods Of Making And Using Same
  申请人：Pfizer Inc.

  公开号：US20170119672A1

  公开（公告）日：2017-05-04

  The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.